Small extracellular vesicles mediated signaling and pain
小细胞外囊泡介导的信号传导和疼痛
基本信息
- 批准号:10685324
- 负责人:
- 金额:$ 42.51万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-09-01 至 2027-05-31
- 项目状态:未结题
- 来源:
- 关键词:AcetylationAdjuvantAdjuvant TherapyAffectAgeAnalgesicsAnti-Inflammatory AgentsArchitectureAttenuatedCellsCellular MorphologyCentral Nervous SystemCirculationCommunicationCytometryDepositionDoseEnhancersEpigenetic ProcessFutureGene ExpressionGoalsGrantHistonesHypersensitivityImmuneImmune responseImmunologic MarkersImmunologic MemoryImmunologicsImmunophenotypingIn SituIn VitroInduction of ApoptosisInjectionsInnate Immune ResponseInterleukin-10Interleukin-6Intrathecal InjectionsLipidsMacrophageMediatingMedicalMemoryMessenger RNAMethylationMicroRNAsMicrogliaModelingModificationMusPainPathologicPhenotypePhysiologicalPlayPreparationProcessProphylactic treatmentProteinsPublic HealthRNA TransportResolutionRoleSerumSignal TransductionSourceSpinalSpinal CordSpinal GangliaSpinal cord posterior hornSystemTNF geneTechnologyTestingTherapeuticTissue SampleTissuesTransforming Growth Factor betaUnited StatesUp-RegulationVertebral columnadaptive immune responseattenuationchromatin immunoprecipitationchronic painchronic pain managementcytokineextracellular vesicleshistone methylationhistone methyltransferaseimmunoregulationimprovedin vivoinflammatory markerinflammatory paininhibitorintercellular communicationlipid mediatorlong term memorymembermonocytemouse modelnovelpain reliefprophylacticrecruitresponsesexsmall moleculeuptakevaccination strategyvesicle transportvesicular release
项目摘要
Abstract
Chronic pain is the most prevalent, disabling, and expensive public health condition in the United
States. The goal of this project is to elucidate how to harness body’s own analgesic mechanisms
to provide pain relief. We propose to investigate 30-150 nm small extracellular vesicles (sEVs)
that transport mRNAs, miRNAs, proteins, and lipid mediators to recipient cells via circulation.
Uptake of sEVs induce gene expression changes in recipient cells and thus, sEVs play an
important role in intercellular communication. We observed that sEVs from RAW 264.7
macrophage cells show therapeutic and prophylactic efficacy in a complete Freud adjuvant (CFA)
mouse model of inflammatory pain. Our preliminary studies show that mouse serum derived sEVs
also conferred prophylaxis when injected intrathecally in naïve recipient mice that, two weeks
later, received a hind paw injection of CFA. Thus, mice that received sEVs can remember this
stimulation for at least 2 weeks and show an attenuated response to CFA. How this long-term
memory develop is unknown. Though chronic pain is prevalent, an immunization strategy has not
yet been tested and our studies will provide the rationale and mechanistic basis for such a
strategy. Here we propose to test the hypothesis that monocyte/macrophage-derived sEV subsets
in serum are necessary and sufficient to attenuate inflammatory pain hypersensitivity and confer
prophylaxis. We will also investigate if monocyte/macrophage sEVs recruit, or promote anti-
inflammatory phenotype switching of immune cells in dorsal root ganglion and spinal cord by
quantitative immunophenotyping in situ, before and after CFA treatment. Recent studies show
that microglia, the resident macrophages of the central nervous system can enhance or suppress
responses to a delayed secondary insult through epigenetic modifications. We hypothesize that
monocyte/macrophage-derived sEVs impart epigenetic immune memory in spinal microglia of
recipient mice, granting the capacity to attenuate pain from a future insult and contribute to the
prophylactic effect of sEVs. The studies proposed will elucidate the role of sEVs in immune
regulation and memory.
摘要
慢性疼痛是美国最普遍、最致残、最昂贵的公共卫生状况
各州。这个项目的目标是阐明如何利用人体自身的止痛机制
来提供止痛药。我们建议研究30-150 nm的细胞外小泡(SEV)
通过循环将mRNAs、miRNAs、蛋白质和脂质介体输送到受体细胞。
SEV的摄取诱导受体细胞中基因表达的变化,因此,SEV发挥着
在细胞间通讯中发挥重要作用。我们观察到RAW 264.7的SEV
巨噬细胞在完全弗洛伊德佐剂(CFA)中显示治疗和预防效果
小鼠炎症性疼痛模型。我们的初步研究表明,小鼠血清来源的SEV
在幼稚的受体小鼠鞘内注射时,也提供了预防,两周
随后,接受后爪注射CFA。因此,接受SEV的小鼠可以记住这一点
刺激至少2周,对CFA的反应减弱。这种长期的
内存开发未知。尽管慢性疼痛很普遍,但免疫策略并没有
我们的研究将提供这样一个理论和机制基础
策略。在这里,我们建议检验单核/巨噬细胞来源的SEV亚群的假设
对于减轻炎性疼痛、过敏性反应和
预防措施。我们还将调查单核/巨噬细胞SEV是否招募或促进抗-
大鼠背根神经节和脊髓免疫细胞炎性表型转换
CFA治疗前后原位定量免疫表型分析。最近的研究表明
小胶质细胞,即驻留在中枢神经系统的巨噬细胞,可以增强或抑制
通过表观遗传修饰对延迟的二次侮辱的反应。我们假设
单核/巨噬细胞来源的SEV在小鼠脊髓小胶质细胞中传递表观遗传免疫记忆
受体小鼠,赋予其减轻未来侮辱带来的疼痛的能力,并有助于
SEV的预防作用。提出的研究将阐明SEV在免疫中的作用
调节和记忆。
项目成果
期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Epigenetic regulation in opioid induced hyperalgesia.
- DOI:10.1016/j.ynpai.2023.100146
- 发表时间:2023-08
- 期刊:
- 影响因子:0
- 作者:Reddy, Deepa;Wickman, Jason R.;Ajit, Seena K.
- 通讯作者:Ajit, Seena K.
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Seena Ajit其他文献
Seena Ajit的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Seena Ajit', 18)}}的其他基金
Small extracellular vesicles mediated signaling and pain
小细胞外囊泡介导的信号传导和疼痛
- 批准号:
10539610 - 财政年份:2022
- 资助金额:
$ 42.51万 - 项目类别:
Immune modulating therapies to treat complex regional pain syndrome
免疫调节疗法治疗复杂的区域疼痛综合征
- 批准号:
10583271 - 财政年份:2022
- 资助金额:
$ 42.51万 - 项目类别:
Exosome-mediated signaling in neuropathic pain
外泌体介导的神经病理性疼痛信号传导
- 批准号:
10183345 - 财政年份:2017
- 资助金额:
$ 42.51万 - 项目类别:
Functional characterization of hsa-mir-939 as a novel regulator of pain
hsa-mir-939 作为新型疼痛调节剂的功能表征
- 批准号:
8626458 - 财政年份:2013
- 资助金额:
$ 42.51万 - 项目类别:
Functional characterization of hsa-mir-939 as a novel regulator of pain
hsa-mir-939 作为新型疼痛调节剂的功能表征
- 批准号:
8492609 - 财政年份:2013
- 资助金额:
$ 42.51万 - 项目类别:
相似海外基金
Countering sympathetic vasoconstriction during skeletal muscle exercise as an adjuvant therapy for DMD
骨骼肌运动期间对抗交感血管收缩作为 DMD 的辅助治疗
- 批准号:
10735090 - 财政年份:2023
- 资助金额:
$ 42.51万 - 项目类别:
The ESCAPE clinical trial of circulating tumor DNA to guide adjuvant therapy in chemo-resistant triple negative breast cancer
循环肿瘤 DNA 指导化疗耐药三阴性乳腺癌辅助治疗的 ESCAPE 临床试验
- 批准号:
494901 - 财政年份:2023
- 资助金额:
$ 42.51万 - 项目类别:
Operating Grants
A Type I Hybrid Effectiveness-Implementation Trial to Evaluate a Navigation-Based Multilevel Intervention to Decrease Delays Starting Adjuvant Therapy Among Patients with Head and Neck Cancer
一项 I 型混合有效性实施试验,用于评估基于导航的多级干预措施,以减少头颈癌患者开始辅助治疗的延迟
- 批准号:
10714537 - 财政年份:2023
- 资助金额:
$ 42.51万 - 项目类别:
Multi-modal machine learning to guide adjuvant therapy in surgically resectable colorectal cancer
多模式机器学习指导可手术切除结直肠癌的辅助治疗
- 批准号:
10588103 - 财政年份:2023
- 资助金额:
$ 42.51万 - 项目类别:
Efficacy of ethanol adjuvant therapy after resection of malignant soft tissue tumors
恶性软组织肿瘤切除术后乙醇辅助治疗的疗效
- 批准号:
22K09407 - 财政年份:2022
- 资助金额:
$ 42.51万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Identification of immune response cells and development of novel adjuvant therapy for sublingual immunotherapy
免疫应答细胞的鉴定和舌下免疫治疗新型辅助疗法的开发
- 批准号:
21KK0287 - 财政年份:2022
- 资助金额:
$ 42.51万 - 项目类别:
Fund for the Promotion of Joint International Research (Fostering Joint International Research (A))
Pursuing molecular biomarkers to guide adjuvant therapy for HPV+ head and neck cancers after transoral robotic surgery
寻找分子生物标志物来指导经口机器人手术后 HPV 头颈癌的辅助治疗
- 批准号:
10357120 - 财政年份:2022
- 资助金额:
$ 42.51万 - 项目类别:
Biomarker research using two prospective studies on preoperative and postoperative adjuvant therapy for pancreatic cancer
使用两项关于胰腺癌术前和术后辅助治疗的前瞻性研究进行生物标志物研究
- 批准号:
21K08700 - 财政年份:2021
- 资助金额:
$ 42.51万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Personalized Resistant Starch as an Adjuvant Therapy for Pediatric Inflammatory Bowel Disease
个性化抗性淀粉作为小儿炎症性肠病的辅助治疗
- 批准号:
437315 - 财政年份:2020
- 资助金额:
$ 42.51万 - 项目类别:
Studentship Programs
Tailored adjuvant therapy in POLE-mutated and p53-wildtype early stage endometrial cancer (TAPER)
POLE 突变和 p53 野生型早期子宫内膜癌 (TAPER) 的定制辅助治疗
- 批准号:
435603 - 财政年份:2020
- 资助金额:
$ 42.51万 - 项目类别:
Operating Grants